OTC: NURPF - Neuren Pharmaceuticals Limited

Altı ay boyunca karlılık: -44.79%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Neuren Pharmaceuticals Limited

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares.

daha fazla ayrıntı
Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://www.neurenpharma.com
Цена ао 10.33
Günlük fiyat değişimi: 0% (7.868)
Haftalık fiyat değişimi: 0% (7.868)
Aylık fiyat değişimi: -1.03% (7.95)
3 ayda fiyat değişimi: -23.83% (10.33)
Altı ayda fiyat değişimi: -44.79% (14.25)
Yıllık fiyat değişimi: -53.66% (16.98)
3 yılda fiyat değişimi: +199.1% (2.6306)
5 yılda fiyat değişimi: +842.28% (0.835)
10 yılda fiyat değişimi: 0% (7.868)
Yılbaşından bu yana fiyat değişimi: -17.18% (9.5)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 12.7 1
P/BV 14.35 1
P/E 18.75 7
EV/EBITDA 14.7 7
Toplam: 5.63

Yeterlik

İsim Anlam Seviye
ROA, % 63.35 10
ROE, % 76.55 10
Toplam: 8.33

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA 0 10
Toplam: 10

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 46756.97 10
karlılık Ebitda, % -1821.79 0
karlılık EPS, % -2025.02 0
Toplam: 2
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Vanguard International Stock Index-Total Intl Stock Indx 1480133 1.16
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 877162 0.69
iShares Core MSCI EAFE ETF 652944 0.51
iShares MSCI EAFE Small Cap ETF 436465 0.34
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 403572 0.32
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 215442 0.17
iShares Core MSCI Total International Stock ETF 140892 0.11
Vanguard International Stock Index-Pacific Stock Index 128668 0.1
College Retirement Equities Fund-Stock Account 85378 0.07
SEI Institutional International Tr-International Equity 71485 0.06



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. CEO, MD & Executive Director 714.28k
Ms. Lauren Frazer C.A. CFO & Company Secretary N/A
Mr. Lawrence Glass BA (Biology) Chief Science Officer N/A
Mr. Gerry Zhao Vice President of Corporate Development N/A
Dr. Liza A. Squires M.D. Chief Medical Officer N/A

Adres: Australia, Camberwell, 697 Burke Road - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.neurenpharma.com